A former information technology (IT) executive at Mylan today pleaded guilty to conspiracy to commit securities fraud and aiding in the preparation of a false tax return. Dayakar Mallu, who at the time of the fraud served as VP of global operations information technology at Mylan, admitted to the charges in court in the Western…

Pfizer (NYSE:PFE) agreed to pay $345 million to settle claims of overpayments for EpiPens due to alleged anti-competitive and unfair practices. Reuters reported that a filing disclosed in federal court in Kansas City, Kan., revealed the settlement set to resolve claims from consumers who say they overpaid for EpiPens with the alleged anti-competitive and unfair practices by…

Pfizer (NYSE:PFE) expects common stock for its Viatris spin-off to be available starting Nov. 12, following the U.S. Federal Trade Commission’s approval of the proposed merger of Mylan (NSDQ:MYL) and Pfizer’s biopharmaceutical Upjohn brand.  The company expects the “when-issued” market for Viatris common stock (VTRSV) to be available from Nov. 12 to Nov. 16, when it…

Mylan (NSDQ:MYL) and Pfizer (NYSE:PFE) recently announced that the U.S. Federal Trade Commission had signed off on the proposed merger of Mylan and Pfizer’s biopharmaceutical-focused Upjohn brand. Upjohn also includes Pfizer’s Greenstone generic-drug unit. It also owns the rights to Lipitor and Xanax. Pfizer plans to spin out Upjohn on Nov. 13. If all goes…

Gilead Sciences’ (NSDQ:GILD) said Tuesday that it has signed licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir, the experimental drug being used in the U.S. to treat COVID-19. The non-exclusive, voluntary agreements allow the companies — Mylan (NSDQ:MYL), Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences — to manufacture remdesivir for distribution in 127…